Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy

Acta Oncologica

Volumn 35, Issue 2, 1996, Pages 149-158

  Sigurdardóttir, Valgerdur ^a,c   Bolund, Christina ^a   Sullivan, Marianne ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Krabbameinsfélag Isl   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; VINDESINE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 0029930563     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098495     Document Type: Article

References (28)

1. Törn M, Adami HO, Bergström R, Ringborg U, Krusemo UB. Trends in survival from malignant melanoma: Remarkable improvement in 23 years. J Natl Cancer Inst 1989; 81: 611-7.
2. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-82.
3. Ringborg U, Rudenstam CM, Hafström L. Hansson J, Strander H. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989; 6: 285-9.
4. Ringborg U, Jungnelius U, Hansson J, Strander H. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: A phase I-II trial. Am J Clin Oncol 1990; 13: 214-7.
5. Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ. Chemotherapy for malignant melanoma: combinations and high doses produce more response without survival benefit. Br J Cancer 1990; 61: 330-4.
6. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-23.
7. de Haes JCJM, van Kippenberg FCF. The quality of life of cancer patients - a review of the literature. Soc Sci Med 1985; 20: 809-17.
8. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology (Huntingt) 1990; 4: 29-38.
9. Aaronson NK, Meyerowitz BE, Bard M, et al. Quality of life reseach in oncology: Past actievements and future priorities. Cancer 1991; 67 (suppl 3): 839-43.
10. Aaronson NK, Ahmedzai S, Bullinger M, et al. The EORTC Core Quality-Of-Life Questionnaire: Interim Results of an International Field Study. In: Osoba D, ed. Effect of Cancer on Quality of Life. Boca Raton, CRC Press Inc., 1991: 185-203.
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
12. Sigurdardóttir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 1993; 2: 193-203.
13. WHO handbook for reporting results of cancer treatment. Geneva, WHO, 1979.
14. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
15. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M, for the EORTC Study Group on Quality of Life. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-42.
16. Bradley JW. Distribution-free statistical tests. London, Prentice-Hall, 1968: 68-86.
17. Bergman B, Sullivan M, Sörenson S. Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile. Acta Oncol 1992; 31: 19-28.
18. Kaasa S, Mastekaasa A, Thorud E. Toxicity, physical function and everyday actively reported by patients with inoperable non-small cell lung cancer in a randomized trial (chemotherapy versus radiotherapy). Acta Oncol 1988; 27: 343-9.
19. Fraser SC, Dobbs HJ, Ebbs SR, Fallowfield LJ, Bates T, Baum M. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 1993; 67: 402-6.
20. Glimelius G, Hoffman K, Ólafsdóttir M, Pahlman L. Sjödén PO. Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989; 25: 829-35.
21. Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky Performance Status and the Functional Living Index-Cancer. Cancer 1988; 61: 849-56.
22. Aaronson NK. Assessing the quality of life of patients in cancer clinical trials: Common problems and common sense solutions. Eur J Cancer 1992; 28 A: 1304-7.
23. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993; 2: 129-39.
24. Cella DT, Orofiamma B, Holland JC, et al. The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer 1987; 60: 1661-7.
25. Plumb M, Holland J. Comparative studies on psychological function in patients with advanced cancer II. Interviewer-rated current and past psychological symptoms. Psychosom Med 1981; 43: 243-54.
26. Hopwood P, Howell A, Maguire P. Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer 1991; 64: 349-52.
27. Kaasa S, Mastekaasa A. Psychosocial well-being of patients with inoperable non-small cell lung cancer. The importance of treatment-and disease-related factors. Acta Oncol 1988; 27: 829-35.
28. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5.